Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2023-09-29
Target enrollment:
Participant gender:
Summary
This study is being done to find out whether the study drug Retifanlimab, a monoclonal
antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and
effective treatment for your disease. Gemcitabine and docetaxel are chemotherapy drugs that
are commonly used to treat soft tissue sarcoma. Retifanlimab is an experimental drug that
boosts the immune system's ability to fight cancer cells. The study researchers think that
Retifanlimab may help gemcitabine and docetaxel work better against soft tissue sarcoma that
is either locally advanced or has spread beyond its original location (metastasized), and it
cannot be removed with surgery (unresectable).